Alan Melcher

16.2k total citations · 1 hit paper
245 papers, 10.5k citations indexed

About

Alan Melcher is a scholar working on Genetics, Oncology and Immunology. According to data from OpenAlex, Alan Melcher has authored 245 papers receiving a total of 10.5k indexed citations (citations by other indexed papers that have themselves been cited), including 158 papers in Genetics, 121 papers in Oncology and 92 papers in Immunology. Recurrent topics in Alan Melcher's work include Virus-based gene therapy research (157 papers), CAR-T cell therapy research (81 papers) and Immunotherapy and Immune Responses (68 papers). Alan Melcher is often cited by papers focused on Virus-based gene therapy research (157 papers), CAR-T cell therapy research (81 papers) and Immunotherapy and Immune Responses (68 papers). Alan Melcher collaborates with scholars based in United Kingdom, United States and Canada. Alan Melcher's co-authors include Richard G. Vile, Kevin J. Harrington, Hardev Pandha, Fiona Errington‐Mais, Peter J. Selby, Timothy Kottke, Jill Thompson, Rosa María Díaz, Robin Prestwich and Elizabeth J. Ilett and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Alan Melcher

238 papers receiving 10.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inflammatory microenvironment remodelling by tumour cells after radiotherapy

2020 601 citations Martin McLaughlin, Emmanuel C. Patin et al. Nature reviews. Cancer profile →

Peers

Countries citing papers authored by Alan Melcher

Since Specialization

Citations

This map shows the geographic impact of Alan Melcher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Melcher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Melcher more than expected).

Fields of papers citing papers by Alan Melcher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Melcher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Melcher. The network helps show where Alan Melcher may publish in the future.

Co-authorship network of co-authors of Alan Melcher

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Melcher. A scholar is included among the top collaborators of Alan Melcher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Melcher. Alan Melcher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprogramming of the tumour microenvironment 2024 ·Frontiers in Immunology ·Victoria A. Jennings, (unknown), G Migneco, (unknown), (unknown), Nicola Ingram, (unknown), (unknown), (unknown), David Jackson, Christy Ralph, Susana Banerjee, Iain A. McNeish, John C. Bell, Alan Melcher, Carolina S. Ilkow, Graham P. Cook, Fiona Errington‐Mais	1
2	FUME-TCRseq Enables Sensitive and Accurate Sequencing of the T-cell Receptor from Limited Input of Degraded RNA 2024 ·Cancer Research ·Ann‐Marie Baker, (unknown), Pablo Nenclares, Tahel Ronel, (unknown), Christopher Kimberley, Miangela M. Laclé, Shreerang Bhide, Kevin J. Harrington, Alan Melcher, Manuel Rodriguez‐Justo, Benny Chain, Trevor A. Graham	3
3	Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling 2024 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), Shane Foo, (unknown), Pablo Nenclares, (unknown), (unknown), Martin McLaughlin, (unknown), (unknown), Victoria Roulstone, Emmanuel C. Patin, Malin Pedersen, Joan Kyula, Masahiro Ono, Fiona Errington‐Mais, John C. Bell, Kevin J. Harrington, Alan Melcher, Victoria A. Jennings	5
4	CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues 2024 ·Molecular Cancer Therapeutics ·James Paget, Janice Ward, (unknown), David Mansfield, Martin McLaughlin, Joan Kyula, Henry Smith, Victoria Roulstone, (unknown), You Zhou, (unknown), Anita Grigoriadis, Devin Coon, Sheeba Irshad, Alan Melcher, Kevin J. Harrington, Aadil Khan	0
5	Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives 2024 ·Cancer Treatment Reviews ·(unknown), Antonio Rullan, (unknown), (unknown), Víctor Moreno, Bernard Doger, (unknown), Derfel ap Dafydd, Alan Melcher, Kevin J. Harrington	6
6	On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy 2021 ·Journal for ImmunoTherapy of Cancer ·Pablo Nenclares, (unknown), (unknown), (unknown), (unknown), Isla Leslie, Kee H. Wong, Alan Melcher, Kate Newbold, Chris Nutting, Derfel ap Dafydd, Shreerang Bhide, Kevin J. Harrington	29
7	Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche 2021 ·Journal for ImmunoTherapy of Cancer ·(unknown), G Migneco, Gina B. Scott, Jenny Down, (unknown), (unknown), Victoria A. Jennings, Babatunde O. Oyajobi, Karen J. Scott, Emma J. West, Christy Ralph, Adel Samson, Elizabeth J. Ilett, Munitta Muthana, Matt Coffey, Alan Melcher, Christopher Parrish, Gordon Cook, Michelle A. Lawson, Fiona Errington‐Mais	14
8	Inflammatory microenvironment remodelling by tumour cells after radiotherapy breakdown → 2020 ·Nature reviews. Cancer ·Martin McLaughlin, Emmanuel C. Patin, Malin Pedersen, Anna Wilkins, Magnus T. Dillon, Alan Melcher, Kevin J. Harrington	601
9	PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma 2019 ·Clinical Cancer Research ·Henry Smith, David Mansfield, Victoria Roulstone, Joan Kyula, Martin McLaughlin, Radhika Patel, Katharina Bergerhoff, James Paget, Magnus T. Dillon, Aadil Khan, Alan Melcher, Khin Thway, Kevin J. Harrington, Andrew Hayes	23
10	Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment 2019 ·Cancer Immunology Research ·Laura Evgin, Amanda L. Huff, Timothy Kottke, Jill Thompson, Amy M. Molan, Christopher B. Driscoll, Matthew Schuelke, Kevin G. Shim, Phonphimon Wongthida, Elizabeth J. Ilett, (unknown), Reuben S. Harris, Matt Coffey, José S. Pulido, Hardev Pandha, Peter J. Selby, Kevin J. Harrington, Alan Melcher, Richard G. Vile	13
11	ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment 2019 ·Clinical Cancer Research ·Magnus T. Dillon, Katharina Bergerhoff, Malin Pedersen, (unknown), (unknown), Emmanuel C. Patin, Alex Pearson, Henry Smith, James Paget, Radhika Patel, Shane Foo, (unknown), Chanthirika Ragulan, Elisa Fontana, Krisha Desai, Anna Wilkins, Anguraj Sadanandam, Alan Melcher, Martin McLaughlin, Kevin J. Harrington	146
12	Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer 2019 ·Clinical Cancer Research ·Nicola Annels, David Mansfield, (unknown), Carmen Ballesteros‐Merino, Guy R. Simpson, (unknown), (unknown), Alan Melcher, Kevin J. Harrington, (unknown), Gough G. Au, Mark Grose, Izhar Bagwan, Bernard A. Fox, Richard G. Vile, Hugh Mostafid, Darren R. Shafren, Hardev Pandha	97
13	The immunological consequences of radiation‐induced DNA damage 2019 ·The Journal of Pathology ·Anna Wilkins, Emmanuel C. Patin, Kevin J. Harrington, Alan Melcher	44
14	Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors 2014 ·Clinical Cancer Research ·Victoria Roulstone, Khurum Khan, Hardev Pandha, Sarah Rudman, Matt Coffey, George M. Gill, Alan Melcher, Richard G. Vile, Kevin J. Harrington, Johann S. de Bono, James Spicer	42
15	Perioperative Influenza Vaccination Reduces Postoperative Metastatic Disease by Reversing Surgery-Induced Dysfunction in Natural Killer Cells 2013 ·Clinical Cancer Research ·Lee‐Hwa Tai, Jiqing Zhang, Karen J. Scott, Christiano Tanese de Souza, Almohanad A. Alkayyal, (unknown), (unknown), Robert A. Adair, Ahmad Bakur Mahmoud, Subash Sad, John C. Bell, Andrew P. Makrigiannis, Alan Melcher, Rebecca C. Auer	56
16	Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies 2012 ·Clinical Cancer Research ·Eleni Karapanagiotou, Victoria Roulstone, Katie Twigger, (unknown), Mary Anne Tanay, Chris Nutting, Kate Newbold, Martin Gore, James Larkin, Konstantinos N. Syrigos, Matt Coffey, Brad Thompson, K.L. Mettinger, Richard G. Vile, Hardev Pandha, Geoff Hall, Alan Melcher, John Chester, Kevin J. Harrington	151
17	Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers 2010 ·Clinical Cancer Research ·Kevin J. Harrington, Eleni Karapanagiotou, Victoria Roulstone, Katie Twigger, Christine L. White, Laura Vidal, (unknown), Robin Prestwich, Kate Newbold, Merina Ahmed, Khin Thway, Christopher M. Nutting, Matt Coffey, Dean Harris, Richard G. Vile, Hardev Pandha, Johann S. de Bono, Alan Melcher	94
18	Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy 2008 ·Clinical Cancer Research ·Katie Twigger, Laura Vidal, Christine L. White, Johann S. de Bono, Shreerang Bhide, Matt Coffey, Brad Thompson, Richard G. Vile, Lucy Heinemann, Hardev Pandha, Fiona Errington‐Mais, Alan Melcher, Kevin J. Harrington	88
19	Inhibition of Repair of Radiation-Induced DNA Damage Enhances Gene Expression from Replication-Defective Adenoviral Vectors 2008 ·Cancer Research ·Mohan Hingorani, Christine L. White, (unknown), (unknown), Martin Gore, Andrew Slade, Simon D. Scott, Christopher M. Nutting, Hardev Pandha, Alan Melcher, Richard G. Vile, Georges Vassaux, Kevin J. Harrington	20
20	Radiation-Mediated Up-Regulation of Gene Expression from Replication-Defective Adenoviral Vectors: Implications for Sodium Iodide Symporter Gene Therapy 2008 ·Clinical Cancer Research ·Mohan Hingorani, Christine L. White, Shane Zaidi, (unknown), (unknown), Martin Gore, Christopher M. Nutting, Hardev Pandha, Alan Melcher, Richard G. Vile, Georges Vassaux, Kevin J. Harrington	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact